NCT04756336View on ClinicalTrials.gov

LTX-109 as Treatment for Hidradenitis Suppurativa

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

LTX-109 gel, 3% w/w

The drug is applied to affected lesions according to treatment regimen

Trial Locations (1)

9038

University Hospital of North Norway, Tromsø

Sponsors

Lead Sponsor

Pharma Holdings AS

All Listed Sponsors

collaborator

University Hospital of North Norway

OTHER

lead

Pharma Holdings AS

INDUSTRY